|

Olaparib Clinical Trials

67 actively recruiting trials across 28 locations

Also known as: (Lynparza Cap), AZD 2281, AZD-2281, AZD2281, KU 0059436 +15 more

Pipeline

Early 1: 2Phase 1: 13Phase 2: 34Phase 3: 5Phase 4: 1Phase 1/2: 9Phase 2/3: 2

Top Sponsors

National Cancer Institute (NCI)8
Merck Sharp & Dohme LLC4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
M.D. Anderson Cancer Center3
University of Colorado, Denver2

Indications

Cancer67
Breast Cancer22
Fallopian Tube Cancer5
BRCA2 Mutation5
BRCA1 Mutation5

Other25 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Phase 2

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Phase 1/2

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Phase 1/2

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Phase 2

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Phase 2

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Phase 1

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Phase 3

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Phase 2

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Phase 2

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Phase 2

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2

Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness

Phase 4

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2

Pilot Trial for Treatment of Recurrent Glioblastoma

Early 1

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Phase 2/3

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Phase 2/3

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Phase 2

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

Phase 1/2

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Phase 2

Birmingham, Alabama5 trials

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

University of Alabama at Birmingham

Phase 1/2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Houston, Texas4 trials

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

MD Anderson Cancer Center

Phase 1/2

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

M D Anderson Cancer Center

Phase 2

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

The University of Texas M. D. Anderson Cancer Center

Phase 1

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

M D Anderson Cancer Center

Phase 1

Baltimore, Maryland3 trials

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Sidney Kimmel Comprehensive Cancer Center

Phase 2

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Phoenix, Arizona2 trials

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Duarte, California2 trials

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 2

Study of INCB123667 in Subjects With Advanced Solid Tumors

City of Hope Medical Center

Phase 1

La Jolla, California2 trials

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

University of California San Diego - Moores Cancer Center

Phase 2

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

UCSD Moores Cancer Center ( Site 0039)

Phase 1/2

Aurora, Colorado2 trials

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado Hospital

Phase 2

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

CU Medicine Clinics

Phase 1

Boston, Massachusetts2 trials

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Beth Israel Deaconess Medical Center

Phase 1

Surgical Pembro +/- Olaparib w TMZ for rGBM

Massachusetts General Hospital

Phase 2

Anchorage, Alaska1 trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Anchorage Associates in Radiation Medicine

Phase 2

Gilbert, Arizona1 trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3

Goodyear, Arizona1 trial

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Investigative Site #108

Phase 1

Tucson, Arizona1 trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Arizona Cancer Center at UMC North ( Site 0018)

Phase 3

Springdale, Arkansas1 trial

Study of LP-184 in Patients With Advanced Solid Tumors

Highlands Oncology Group

Phase 1/2

Encinitas, California1 trial

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

UC San Diego Health System - Encinitas

Phase 2

Fountain Valley, California1 trial

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Exelixis Clinical Site #12

Phase 1

Irvine, California1 trial

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

San Francisco, California1 trial

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1

Santa Monica, California1 trial

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2

West Los Angeles, California1 trial

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Phase 2

Orlando, Florida1 trial

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Advent Health

Phase 3

Tampa, Florida1 trial

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Moffitt Cancer Center

Phase 2

Chicago, Illinois1 trial

Olaparib in Patients With HRD Malignant Mesothelioma

University of Chicago Medical Center

Phase 2

Lexington, Kentucky1 trial

Pembro With Radiation With or Without Olaparib

University of Kentucky

Phase 2

Bethesda, Maryland1 trial

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center

Phase 1/2

Lebanon, New Hampshire1 trial

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Dartmouth Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Teaneck, New Jersey1 trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Holy Name Medical Center /ID# 279017

Phase 2

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.